Full-size Left-side Hidden

4.. Rothova A: Ocular involvement in sarcoidosis. Br J Ophthalmol  2000; 84:110-116.

6.. Lertsumitkul S, Whitcup SM, Nussenblatt RB, et al: Subretinal fibrosis and choroidal neovascularization in Vogt–Koyanagi–Harada syndrome. Graefes Arch Clin Exp Ophthalmol  1999; 237:1039-1045.

7.. Nussenblatt RB, Gery I, Ballintine EJ, et al: Cellular immune responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol  1980; 89:173-179.

8.. Ham DI, Gentleman S, Chan CC, et al: RPE65 is highly uveitogenic in rats. Invest Ophthalmol Vis Sci  2002; 43:2258-2263.

9.. Broekhuyse RM, Winkens HJ, Kuhlmann ED: Induction of experimental autoimmune uveoretinitis and pinealitis by IRBP. Comparison to uveoretinitis induced by S-antigen and opsin. Curr Eye Res  1986; 5:231-240.

10.. Chan CC, Nussenblatt RB, Wiggert B, et al: Immunohistochemical analysis of experimental autoimmune uveoretinitis (EAU) induced by interphotoreceptor retinoid-binding protein (IRBP) in the rat. Immunol Invest  1987; 16:63-74.

11.. Nussenblatt RB, Rodrigues MM, Wacker WB, et al: Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest  1981; 67:1228-1231.

12.. Whitcup SM, Wakefield D, Li Q, et al: Endothelial leukocyte adhesion molecule-1 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci  1992; 33:2626-2630.

13.. Verhagen C, Mor F, Cohen IR: T cell immunity to myelin basic protein induces anterior uveitis in Lewis rats. J Neuroimmunol  1994; 53:65-71.

14.. Broekhuyse RM, Kuhlmann ED, Winkens HJ: Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp Eye Res  1992; 55:401-411.

15.. Kim MC, Kabeer NH, Tandhasetti MT, et al: Immunohistochemical studies on melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU). Curr Eye Res  1995; 14:703-710.

16.. Yamaki K, Takiyama N, Itho N, et al: Experimentally induced Vogt–Koyanagi–Harada disease in two Akita dogs. Exp Eye Res  2005; 80:273-280.

17.. Hayakawa K, Ishikawa M, Yamaki K: Ultrastructural changes in rat eyes with experimental Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol  2004; 48:222-227.

18.. Anderson A, Clifford W, Palvolgyi I, et al: Immunopathology of chronic experimental histoplasmic choroiditis in the primate. Invest Ophthalmol Vis Sci  1992; 33:1637-1641.

19.. Hu MS, Schwartzman JD, Lepage AC, et al: Experimental ocular toxoplasmosis induced in naive and preinfected mice by intracameral inoculation. Ocul Immunol Inflamm  1999; 7:17-26.

21.. Levinson RD: Immunogenetics of ocular inflammatory disease. Tissue Antigens  2007; 69:105-112.

22.. Malaviya AN, Mehra NK, Adhar G, et al: HLA B27 in patients with seronegative spondarthritides. J Rheumatol  1979; 6:413-416.

24.. Baarsma GS, Priem HA, Kijlstra A: Association of birdshot retinochoroidopathy and HLA-A29 antigen. Curr Eye Res  1990; 9(Suppl.):63-68.

25.. Mizuki N, Ohno S, Tanaka H, et al: Association of HLA-B51 and lack of association of class II alleles with Behçet's disease. Tissue Antigens  1992; 40:22-30.

26.. Balboni A, Pivetti-Pezzi P, Orlando P, et al: Serological and molecular HLA typing in Italian Behçet's patients: significant association to B51-DR5-DQw3 haplotype. Tissue Antigens  1992; 39:141-143.

27.. Weisz JM, Holland GN, Roer LN, et al: Association between Vogt–Koyanagi–Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology  1995; 102:1012-1015.

28.. Malinowski SM, Pulido JS, Goeken NE, et al: The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology  1993; 100:1199-1205.

29.. El-Shabrawi Y, Wegscheider BJ, Weger M, et al: Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology  2006; 113:695-700.

30.. Kuo NW, Lympany PA, Menezo V, et al: TNF-857T, a genetic risk marker for acute anterior uveitis. Invest Ophthalmol Vis Sci  2005; 46:1565-1571.

31.. Menezo V, Bond SK, Towler HM, et al: Cytokine gene polymorphisms involved in chronicity and complications of anterior uveitis. Cytokine  2006; 35:200-206.

33.. Takase H, Yu CR, Ham DI, et al: Inflammatory processes triggered by TCR engagement or by local cytokine expression: differences in profiles of gene expression and infiltrating cell populations. J Leukoc Biol  2006; 80:538-545.

35.. Latkany PA, Jabs DA, Smith JR, et al: Multifocal choroiditis in patients with familial juvenile systemic granulomatosis. Am J Ophthalmol  2002; 134:897-904.

36..  In: Nussenblatt RB, Whitcup SW, ed. Uveitis: Fundamentals and Clinical Practice,  3rd edn. Philadelphia: Mosby; 2004.

37.. Lightman S, Chan CC: Immune mechanisms in choroido-retinal inflammation in man. Eye  1990; 4:345-353.

38.. Nussenblatt RB, Fortin E, Schiffman R, et al: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA  1999; 96:7462-7466.

39.. Murphy CC, Duncan L, Forrester JV, et al: Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol  2004; 88:412-416.

41.. Ohta K, Yoshimura N: Bcl-2 expression by CD4 T lymphocytes in Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm  2002; 10:93-103.

42.. Kilmartin DJ, Fletcher ZJ, Almeida JA, et al: CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci  2001; 42:1285-1292.

43.. Yu HG, Lee DS, Seo JM, et al: The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet's uveitis. Clin Exp Immunol  2004; 137:437-443.

45.. Chi W, Yang P, Li B, et al: IL-23 promotes CD4+ T cells to produce IL-17 in Vogt–Koyanagi–Harada disease. J Allergy Clin Immunol  2007; 119:1218-1224.

46.. Keino H, Takeuchi M, Usui Y, et al: Supplementation of CD4+CD25+ regulatory T cells suppresses experimental autoimmune uveoretinitis. Br J Ophthalmol  2007; 91:105-110.

48.. Palestine AG, Nussenblatt RB, Chan CC, et al: Histopathology of the subretinal fibrosis and uveitis syndrome. Ophthalmology  1985; 92:838-844.

49.. Kim MK, Chan CC, Belfort Jr R, et al: Histopathologic and immunohistopathologic features of subretinal fibrosis and uveitis syndrome. Am J Ophthalmol  1987; 104:15-23.

50.. Chan CC, Palestine AG, Kuwabara T, et al: Immunopathologic study of Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol  1988; 105:607-611.

51.. Kaplan HJ, Waldrep JC, Chan WC, et al: Human sympathetic ophthalmia. Immunologic analysis of the vitreous and uvea. Arch Ophthalmol  1986; 104:240-244.

52.. Lim WK, Chee SP, Sng I, et al: Immunopathology of progressive subretinal fibrosis: a variant of sympathetic ophthalmia. Am J Ophthalmol  2004; 138:475-477.

53.. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al: Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA  2006; 103:5941-5946.

54.. Li Z, Lim WK, Mahesh SP, et al: Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol  2005; 174:5187-5191.

56.. Brito BE, O’Rourke LM, Pan Y, et al: IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci  1999; 40:2583-2589.

57.. Torun N, Callizo J, Orlic N, et al: Serum cytokine receptor levels in noninfectious uveitis. Ophthalm Res  2005; 37:112-116.

58.. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al: Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalm Res  2001; 33:251-255.

59.. Lacomba MS, Martin CM, Chamond RR, et al: Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol  2000; 118:768-772.

60.. Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, et al: Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin  2004; 20:155-157.

61.. El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology  2002; 109:2342-2346.

62.. Teoh SC, Sharma S, Hogan A, et al: Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol  2007; 91:263-264.

63.. Turan B, Gallati H, Erdi H, et al: Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol  1997; 24:128-132.

64.. Accorinti M, Pirraglia MP, Paroli MP, et al: Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol  2007; 51:191-196.

65.. Niccoli L, Nannini C, Benucci M, et al: Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatol (Oxf)  2007; 46:1161-1164.

66.. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al: Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye  2005; 19:841-845.

67.. Verma MJ, Lloyd A, Rager H, et al: Chemokines in acute anterior uveitis. Curr Eye Res  1997; 16:1202-1208.

68.. Fang IM, Lin CP, Yang CM, et al: Expression of CX3C chemokine, fractalkine, and its receptor CX3CR1 in experimental autoimmune anterior uveitis. Mol Vis  2005; 11:443-451.

69.. Abu El-Asrar AM, Struyf S, Descamps FJ, et al: Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol  2004; 138:401-411.

71.. Cordero Coma M, Sobrin L, Onal S, et al: Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology  2007; 114:1574-1579.

72.. Whitcup SM, Chan CC, Li Q, et al: Expression of cell adhesion molecules in posterior uveitis. Arch Ophthalmol  1992; 110:662-666.

73.. Whitcup SM, DeBarge LR, Caspi RR, et al: Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol  1993; 67:143-150.

74.. Dubertret L, Sterry W, Bos JD, et al: Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol  2006; 155:170-181.

75.. Vincenti F, Mendez R, Pescovitz M, et al: A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant  2007; 7:1770-1777.

76.. Caspi RR: Ocular autoimmunity: the price of privilege?. Immunol Rev  2006; 213:23-35.

77.. Egwuagu CE, Charukamnoetkanok P, Gery I: Thymic expression of autoantigens correlates with resistance to autoimmune disease. J Immunol  1997; 159:3109-3112.

78.. Nagamine K, Peterson P, Scott HS, et al: Positional cloning of the APECED gene. Nat Genet  1997; 17:393-398.

79.. Anderson MS, Venanzi ES, Klein L, Chen Z, et al: Projection of an immunological self shadow within the thymus by the aire protein. Science  2002; 298:1395-1401.

80.. DeVoss J, Hou Y, Johannes K, et al: Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med  2006; 203:2727-2735.

81.. Hsieh CS, Liang Y, Tyznik AJ, et al: Recognition of the peripheral self by naturally arising CD25+CD4+ T cell receptors. Immunity  2004; 21:267-277.

82.. Verbsky JW: Therapeutic use of T regulatory cells. Curr Opin Rheumatol  2007; 19:252-258.

83.. Nussenblatt RB, Caspi RR, Mahdi R, et al: Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol  1990; 144:1689-1695.

84.. Nussenblatt RB, Gery I, Weiner HL, et al: Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol  1997; 123:583-592.

85.. Jabs DA, Akpek EK: Immunosuppression for posterior uveitis. Retina  2005; 25:1-18.

87.. Niccoli L, Nannini C, Benucci M, et al: Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatol (Oxf)  2007; 46:1161-1164.

88.. Abu El-Asrar AM, Abboud EB, Aldibhi H, et al: Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol  2005; 26:83-92.

89.. El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology  2002; 109:2342-2346.

90.. Richards JC, Tay-Kearney ML, Murray K, et al: Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol  2005; 33:461-468.

91.. Rajaraman RT, Kimura Y, Li S, et al: Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology  2006; 113:308-314.

92.. Biester S, Deuter C, Michels H, et al: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol  2007; 91:319-324.

93.. Mushtaq B, Saeed T, Situnayake RD, et al: Adalimumab for sight-threatening uveitis in Behçet's disease. Eye  2007; 21:824-825.

95.. Reddy AR, Backhouse OC: Does etanercept induce uveitis?. Br J Ophthalmol  2003; 87:925.

96.. Nashan B, Light S, Hardie IR, et al: Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation  1999; 67:110-115.

97.. Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol  2007; 27:1-18.

98.. Nussenblatt RB, Fortin E, Schiffman R, et al: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA  1999; 96:7462-7466.

99.. Nussenblatt RB, Thompson DJ, Li Z, et al: Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun  2003; 21:283-293.

100.. Kiss S, Ahmed M, Letko E, et al: Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology  2005; 112:1066-1071.

101.. Gallagher M, Quinones K, Cervantes-Castañeda RA, et al: Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol  2007; 91:1341-1344.